Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy

Acta Haematologica

Volumn 137, Issue 2, 2017, Pages 76-85

  Park, Young Hoon ^a,b   Yi, Hyeon Gyu ^b   Lee, Moon Hee ^b   Kim, Chul Soo ^b   Lim, Joo Han ^b  

^a Hanil General Hospital   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Inflammation; Prognostic factor; Response

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISONE; R-CHOP PROTOCOL; TUMOR MARKER;

ADULT; ADVANCED LUNG CANCER INFLAMMATION INDEX; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE ASSESSMENT; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MORTALITY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREDNISONE; SURVIVAL RATE; VINCRISTINE;

EID: 85009350195     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000452991     Document Type: Article

References (45)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
3. Coiffier B: State-of-The-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387-6393.
4. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD: International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 2002; 94: 3083-3088.
5. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
6. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R: Prediction of survival in diffuse large-Bcell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-1837.
7. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
8. Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, Blomqvist C, Enblad G, Leppa S: Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large Bcell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
9. Younes A: XIV. The rationale for combining targeted and biological anti-lymphoma drugs. Hematol Oncol 2013; 1: 81-83.
10. Younes A, Berry DA: From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol 2012; 9: 643-653.
11. Carbone A, Tripodo C, Carlo-Stella C, Santoro A, Gloghini A: The role of inflammation in lymphoma. Adv Exp Med Biol 2014; 816: 315-333.
12. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
13. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008; 454: 436-444.
14. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastrooesophageal cancer. Br J Cancer 2006; 94: 1568-1571.
15. Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA: C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 2007; 107: 114-117.
16. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R: Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 2009; 45: 912-914.
17. Chua W, Charles KA, Baracos VE, Clarke SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295.
18. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN: Blood neutrophilto-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009; 16: 614-622.
19. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC: Evaluation of an inflammationbased prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006; 94: 637-641.
20. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH: Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol 2012; 33: 749-756.
21. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197: 466-472.
22. Johnson ME, Turaka A, Zhu F, Galloway T, Farma J, Perlis C: Absolute lymphocyte count: a novel prognostic factor for Merkel cell carcinoma. Pract Radiat Oncol 2013; 3(2 Suppl 1):S10-11.
23. Jiang R, Cai XY, Yang ZH, Yan Y, Zou X, Guo L, Sun R, Luo DH, Chen QY, Huang PY, Xiang YQ, Lu X, Wang L, Xia WX, Mai HQ, Chen MY: Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. Chin J Cancer 2015; 34: 237-246.
24. Jafri SH, Shi R, Mills G: Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 2013; 13: 158.
25. Feng JF, Huang Y, Chen QX: A new inflammation index is useful for patients with esophageal squamous cell carcinoma. Onco Targets Ther 2014; 7: 1811-1815.
26. He X, Zhou T, Yang Y, Hong S, Zhan J, Hu Z, Fang W, Qin T, Ma Y, Zhao Y, Cheng Z, Huang Y, Zhao H, Yang G, Zhang L: Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer 2015; 16:e165-e171.
27. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
28. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN: An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large Bcell lymphoma treated in the rituximab era. Blood 2014; 123: 837-842.
29. Morse HC 3rd, Kearney JF, Isaacson PG, Carroll M, Fredrickson TN, Jaffe ES: Cells of the marginal zone-origins, function and neoplasia. Leuk Res 2001; 25: 169-178.
30. Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, Neumeister P, Pichler M: The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 2014; 110: 369-374.
31. Keam B, Ha H, Kim TM, Jeon YK, Lee SH, Kim DW, Kim CW, Heo DS: Neutrophil-tolymphocyte ratio improves prognostic prediction of the International Prognostic Index for patients with diffuse large B cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2015; 56: 2032-2038.
32. Jung SH, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ: Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma. Acta Haematol 2015; 133: 10-17.
33. Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, Qiu MZ, Cai XY, Jin Y, Sun YL, Jiang WQ: Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 2012; 33: 1039-1044.
34. Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M: C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 2014; 111: 55-60.
35. Kim Y, Kim SJ, Hwang D, Jang J, Hyun SY, Kim YR, Kim JS, Min YH, Cheong JW: The modified Glasgow Prognostic Score as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei Med J 2014; 55: 1568-1575.
36. Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, Shen Z: The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol 2015; 94: 5763.
37. Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B: Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 2014; 93: 1305-1312.
38. Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R: Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol 2015, E-pub ahead of print.
39. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN: Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55: 2728-2738.
40. Hwang HS, Yoon DH, Suh C, Huh J: Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified. Ann Hematol 2015; 94: 1655-1665.
41. Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A: Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol 2014; 25: 171-176.
42. McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-226.
43. Tan CS, Read JA, Phan VH, Beale PJ, Peat JK, Clarke SJ: The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. Support Care Cancer 2015; 23: 385-391.
44. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil/lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184.
45. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown RS, Jr, Emond JC: Negative impact of neutrophil/lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-151.